About The Gazette Search Back Issues Contact Us    
The newspaper of The Johns Hopkins University November 15, 2004 | Vol. 34 No. 12
New Gene Target Found for Common Brain Tumors in Children

By Vanessa Wasta
Johns Hopkins Medicine

Scientists at Johns Hopkins have linked a stem-cell gene called Notch2 to a portion of one of the most common childhood brain cancers, opening the door to tailored therapies that block the gene's tumor-promoting ability.

The gene, whose pathway is known to be an important factor in regulating brain stem-cell growth and survival, has been studied in fruit flies for almost a century. The research team at the Johns Hopkins Pathology Department and Kimmel Cancer Center found that a protein made by the gene promotes cancer cell growth by 27 percent in a childhood brain tumor called medulloblastoma. Their studies, reported in the Nov. 1 issue of Cancer Research, also revealed that children with high Notch2 gene activity fared worse in the course of their disease than those with less activity in Notch2.

The researchers report that a drug first developed for Alzheimer's disease called DFK-167, which blocks activation of all Notch proteins, reduces growth of cancerous cells in culture by 80 percent, although unwanted side effects and dosing problems may make it a poor choice for treating human brain cancer. But the investigators are testing more potent drugs of the same class and developing new ones that block only the Notch2 pathway.

No clinical trials with any drug have yet been planned, the researchers emphasize.

Scientists say that gene amplification — a process in which cells make too many copies of a gene — is one of the most reliable indicators of a gene's importance to cancer development. The Johns Hopkins team found Notch2 amplified in six of 40 medulloblastomas and other similar brain tumors.

"Just like genetic mutations, amplifications are long-lasting DNA mistakes, as opposed to transient changes in the production of proteins and other gene products," said Charles Eberhart, assistant professor of pathology. "Finding amplification of Notch2 is a smoking gun tying it to the development of these brain tumors."

In their study, the Johns Hopkins scientists compared levels of a protein marker for Notch2 gene activity to the survival of 35 medulloblastoma patients. Of 11 patients with high levels, seven died; of 24 patients with no detectable protein, only six died.

Standard surgery and radiation for medulloblastoma cures approximately 60 percent of children but often results in many neurological and learning disabilities.

"We'd like to develop a drug that only affects the Notch2 pathway, since blocking other members of the Notch family may actually have the opposite effect and encourage cancer growth," said Xing Fan, first author of the study and postgraduate fellow.

In 25 of 30 of the medulloblastomas it studied, Eberhart's team also found lower levels of Notch1, compared to Notch2, gene products. Notch1 proteins normally provide a brake on growth of medulloblastoma cells, and blocking their activation would cancel out some of the drug's effects. "The net effect of any drug will depend on how much of each Notch1 and Notch2 is present, and since we found more Notch2, we think the scale can be tipped toward stopping the cancer," Eberhart said.

This research was funded by the Children's Brain Tumor Foundation, National Institute of Neurological Disorders and Stroke, and National Cancer Institute. Other JHU research participants are Irina Mikolaenko, Ihab Elhassan, Xing Zhi Ni, Yunyue Wang and Douglas Ball.


The Gazette | The Johns Hopkins University | Suite 540 | 901 S. Bond St. | Baltimore, MD 21231 | 443-287-9900 |